Viking Therapeutics

VKTX

Market cap $3.91B

Eli Lilly (LLY 1.71%) is the largest pharmaceutical (and healthcare) company in the world by market capitalization. It boasts more than 49,000 employees and currently leads the fast-growing market for weight management medicines.

Conference Call Scheduled for Wednesday, October 22 at 4:30 p.m. Eastern Time  SAN DIEGO , Oct. 15, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2025 after the market close on Wednesday, October 22, 2025.

Viking Therapeutics, Inc. (VKTX) closed at $33.05 in the latest trading session, marking a -2.54% move from the prior day.

Viking Therapeutics (VKTX -0.13%) soared to the forefront almost two years ago when it announced data on an investigational drug to serve an area of high need: weight loss. The biotech's candidate met the goals of its phase 2 trial, bringing it a step closer to entering this market that analysts say may approach $100 billion by the end of this decade.

Shares in Viking Therapeutics (VKTX 6.15%) were up more than 16% in the week to Thursday at 1 pm. The move comes after the announcement of another acquisition of a small-cap biopharmaceutical company by a pharmaceutical giant.

Viking Therapeutics offers a de-risked, asymmetric investment opportunity in the GLP-1 weight-loss drug market, trading below its risk-adjusted potential. VKTX's injectable and oral VK2735 both met Phase 2 endpoints, with discontinuation issues in the oral form likely fixable through slower titration and different dosing. Strong cash reserves, committed manufacturing partner, and a diversified pipeline (including VK2809 for MASH) position VKTX for long-term value creation or strategic or financial buyout/going private.

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $27.88, denoting a +1.86% move from the preceding trading day.

Developing GLP-1 medicines is all the rage these days in the pharmaceutical and biotech industries. The market is growing rapidly, and many (if not most) leading drugmakers are looking to capitalize on the trend.

Viking Therapeutics trades at yearly lows despite being ahead of recently acquired competitor Metsera in the weight-loss drug race. The Metsera deal suggests up to 150% upside to Viking, especially when compared to Pfizer's $7.2 billion buyout price, including milestone CVRs. VKTX's oral and injectable weight-loss drugs show promising results, with Phase 3 trials already ongoing and potential to outperform Metsera.

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.09, indicating a -5.78% shift from the previous trading day.